News | October 06, 2014

ProNova and medPhoton to Offer Next Generation Beam Delivery, Advanced Imaging for Proton Therapy

ProNova medPhoton Next Generation Beam Delivery Advanced Imaging Proton Therapy

October 6, 2014 — ProNova Solutions and medPhoton announced that they have agreed to form an exclusive partnership that will merge leading edge pencil beam IMPT and innovative integrated imaging into a unique next generation offering for the proton therapy market.

ProNova will integrate the medPhoton ImagingRing system into the SC360 proton therapy solution. The resulting system will include Fast Scanning IMPT technology with integrated 3-D imaging. This unique solution merges leading edge pencil beam delivery, innovative dual-energy 3-D imaging capability and precision positioning to aid physicians and therapists in minimizing collateral damage to healthy tissue and maximizing dose to the tumor. The ProNova compact superconducting gantry design allows for 360 degrees of patient treatment angle and improved workflow, resulting in faster treatment times and higher productivity.

medPhoton´s newly developed ImagingRing system is a slim, couch based, in-room CBCT device, capable of large field of view, low dose, single source dual energy 3-D volumetric and 2-D planar image acquisitions. It supports smooth workflows and highest precision in inter- and intrafractional image guided radiotherapy.

“medPhoton is glad that our hard research and development work over the last years will now have a real impact on the field. After having installed our first unit at the carbon beam facility MedAustron, we will now integrate our slim imaging ring system with ProNova’s cutting edgesmall footprint proton therapy equipment. In combination of both systems, precise beam adaptation and tracking of moving targets will be possible in the near future. A series of joint installations, research and clinical has been ordered,” says Heinz Deutschmann, chief executive officer and founder of medPhoton.

“ProNova is proud to partner with an innovative company like medPhoton,” said Joe Matteo, division president of ProNova Solutions, R&D and manufacturing. “Together we feel that this unique solution will enable clinicians to develop advanced proton therapy protocols for Adaptive Therapy.”

For more information: www.medphoton.at, pronovasolutions.com

Related Content

Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...